肺癌患者初次免疫与加强接种后对COVID-19 mRNA疫苗的抗体应答:对SARS-CoV-2野生型病毒与奥密克戎变异株的反应性
研究纳入82例非小细胞肺癌患者和53名健康志愿者,纵向采集血液,评估COVID-19 mRNA疫苗基础两剂及加强接种后的结合抗体与中和抗体应答。多数患者应答与健康接种者相当,但25%患者应答差,总体滴度较健康队列低6至7倍;加强接种可显著提高对野生型和奥密克戎的中和抗体滴度,但加强后2至4个月中和滴度下降5至7倍。
要点
- 25%的非小细胞肺癌患者对mRNA疫苗应答差,总体抗体滴度较健康队列低6至7倍。
- 患者对奥密克戎变异株的中和抗体滴度显著低于野生型株。
- 加强接种显著提高结合与中和抗体滴度,但2至4个月后中和滴度下降5至7倍。
核心结论
- 一部分非小细胞肺癌患者对SARS-CoV-2 mRNA疫苗应答差,对B.1.1.529奥密克戎变异株的中和抗体低。
- 加强接种提高了对奥密克戎的结合与中和抗体滴度,但抗体滴度在3个月后下降。
- 鉴于SARS-CoV-2奥密克戎变异株快速传播,这些数据凸显了对癌症患者的担忧。
研究设计与样本
- 研究纳入82例非小细胞肺癌患者和53名健康志愿者,均接受SARS-CoV-2 mRNA疫苗。
- 纵向采集血液,分别用Meso Scale Discovery法和活病毒焦点减少中和试验评估SARS-CoV-2特异性结合抗体与中和抗体应答。
主要发现
- 多数非小细胞肺癌患者在mRNA疫苗接种后产生的结合与中和抗体滴度与健康接种者相当,但25%的患者应答差,导致总体滴度较健康队列低6至7倍(P < .0001)。
- 年龄>70岁的患者免疫球蛋白G滴度较低(P < .01)。
- 接受程序性死亡受体1单药治疗、化疗或两者联合治疗的患者,抗体应答未受显著影响。
- 对B.1.617.2(德尔塔)、B.1.351(贝塔)尤其B.1.1.529(奥密克戎)变异株的中和抗体滴度显著低于614D(野生型)株(P < .0001)。
- 加强接种使针对野生型和奥密克戎变异株的结合与中和抗体滴度显著升高(P = .0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine COVID-19 mRNA vaccine-induced binding and neutralizing antibody responses in patients with non-small-cell lung cancer (NSCLC) to SARS-CoV-2 614D (wild type [WT]) strain and variants of concern after the primary 2-dose and booster vaccination. METHODS: Eighty-two patients with NSCLC and 53 healthy volunteers who received SARS-CoV-2 mRNA vaccines were included in the study. Blood was collected longitudinally, and SARS-CoV-2-specific binding and neutralizing antibody responses were evaluated by Meso Scale Discovery assay and live virus Focus Reduction Neutralization Assay, respectively. RESULTS: A majority of patients with NSCLC generated binding and neutralizing antibody titers comparable with the healthy vaccinees after mRNA vaccination, but a subset of patients with NSCLC (25%) made poor responses, resulting in overall lower (six- to seven-fold) titers compared with the healthy cohort (P = < .0001). Although patients age > 70 years had lower immunoglobulin G titers (P = < .01), patients receiving programmed death-1 monotherapy, chemotherapy, or a combination of both did not have a significant impact on the antibody response. Neutralizing antibody titers to the B.1.617.2 (Delta), B.1.351 (Beta), and in particular, B.1.1.529 (Omicron) variants were significantly lower (P = < .0001) compared with the 614D (WT) strain. Booster vaccination led to a significant increase (P = .0001) in the binding and neutralizing antibody titers to the WT and Omicron variant. However, 2-4 months after the booster, we observed a five- to seven-fold decrease in neutralizing titers to WT and Omicron viruses. CONCLUSION: A subset of patients with NSCLC responded poorly to the SARS-CoV-2 mRNA vaccination and had low neutralizing antibodies to the B.1.1.529 Omicron variant. Booster vaccination increased binding and neutralizing antibody titers to Omicron, but antibody titers declined after 3 months. These data highlight the concern for patients with cancer given the rapid spread of SARS-CoV-2 Omicron variant.
引用
- Valanparambil RM, Carlisle J, Linderman SL, et al. Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. J Clin Oncol. 2022. PMID: 35759727. doi:10.1200/JCO.21.02986
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。